212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...
The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...
This segment outlines how immune checkpoint inhibitors have become essential in bladder cancer management, examining their roles across treatment lines and the current standards of care. This program ...
The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled, ...
64Cu-SAR-bisPSMA showed superior detection of PSMA-positive lesions compared to 68Ga-PSMA-11 in patients with low PSA levels. The Co-PSMA trial enrolled 50 patients with biochemical recurrence ...
The Voro Urologic Scaffold aims to manage stress urinary incontinence by supporting the bladder neck and preserving urethral length post-prostatectomy. A Category III CPT code for the Voro Scaffold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback